
    
      To assess the longer term safety, tolerability, immunogenicity, PK, PD and LDL C lowering
      efficacy after 52 weeks of additional treatment with LIB003 with subcutaneous (SC) dosing
      every 4 weeks (Q4W) in patients on stable maximally tolerated statins with or without
      ezetimibe who completed the phase 2 dose ranging trial LIB003-002
    
  